00:00
Growing Money
Growing Money
USD/RUB
EUR/RUB
Releases

Basecamp Research Integrates EDEN Models into Anthropic's Claude

Drug-resistant infections claim nearly 5 million lives annually, but a new integration between Basecamp Research and Anthropic aims to reverse that trend. By bringing EDEN biological design models into the Claude Science workbench, researchers can now generate and prioritize antibiotic and vaccine candidates through a conversational interface in minutes.

Basecamp Research Integrates EDEN Models into Anthropic's Claude

The collaboration leverages Basecamp Research’s EDEN models, which were trained on BaseData—a massive biological dataset containing over 10 billion genes sourced from diverse global environments, including deep-sea sediment and polar ice. In laboratory trials conducted alongside the University of Pennsylvania’s Machine Biology Group, 97% of peptides designed by EDEN proved active against WHO-designated priority pathogens. César de la Fuente, who led the research, noted that the model produced the candidate EDEN-7 without iterative engineering, achieving efficacy comparable to last-line antibiotics in mice infected with multidrug-resistant Acinetobacter baumannii.

Beyond antibiotic discovery, the integration accelerates vaccine development by identifying proteins likely to trigger protective immune responses. This process replaces months of empirical laboratory work with a streamlined workflow accessible through Claude. Anthropic’s Jonah Cool emphasized that providing researchers with these tools is essential for tackling urgent public health threats. To ensure the project's long-term growth, Basecamp Research is expanding its data collection through the Trillion Gene Atlas, a multi-partner initiative involving NVIDIA, PacBio, and Ultima Genomics. Each data point remains traceable to its origin, with benefit-sharing agreements ensuring that local communities receive a portion of the value generated by the biological insights discovered in their regions.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!